Your browser doesn't support javascript.
loading
Combating COVID-19 with mesenchymal stem cell therapy.
Rajarshi, Keshav; Chatterjee, Aroni; Ray, Shashikant.
Afiliação
  • Rajarshi K; School of Community Science and Technology (SOCSAT) Indian Institute of Engineering Scince and Technology (IIEST), Shibpur, Howrah, West Bengal, 711103, India.
  • Chatterjee A; Indian Council of Medical Research (ICMR)-Virus Research Laboratory, NICED, Kolkata, India.
  • Ray S; Department of Biotechnology, Mahatma Gandhi Central University, Motihari, 845401, India.
Biotechnol Rep (Amst) ; 26: e00467, 2020 Jun.
Article em En | MEDLINE | ID: mdl-32420049
ABSTRACT
The COVID-19 disease is caused by a positive stranded RNA virus called SARS-CoV-2. The virus mainly targets the pulmonary epithelial cells as it's initial site of infection by letting its surface spike protein interact and bind to the host ACE2 receptor. The internalization and gradual replication of the virus results in an exaggerated immune response triggering release of many pro-inflammatory cytokines and chemokines. This immune storm is responsible for multiple health hazards in the host ultimately leading to multiple organ failure. Mesenchymal stem cell therapy offers a promising approach towards mitigating the delirious effects of the infection in the COVID-19 patients. This therapy has shown to reduce the expression of pro-inflammatory cytokines as well as repair of damaged tissues in COVID-19 patients. This review has been organized to put forward the positive aruments and implications in support of mesenchymal stem cell therapy as a necessary approach for treating COVID-19 patients.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Biotechnol Rep (Amst) Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Índia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Biotechnol Rep (Amst) Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Índia